DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuan...
(Thomson Reuters ONE) -
DSM Sinochem Pharmaceuticals (DSP), the global leader in production and
commercialization of sustainable, enzymatic antibiotics, next generation statins
and anti-fungals, announced that it has filed a lawsuit against CSPC
Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company
Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd. for patent
infringement.
SINGAPORE, Oct. 09, 2017 (GLOBE NEWSWIRE) -- DSM Sinochem Pharmaceuticals
announced today that its wholly owned subsidiary, DSM Sinochem Pharmaceuticals
Netherlands B.V. filed a lawsuit against CSPC Pharmaceutical Group Ltd., Inner
Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo
Pharmaceutical (Shijiazhuang) Company Ltd. ("CSPC") for patent infringement in
the District Court of The Hague, Afdeling Handel (commercial division),
Netherlands, for patent infringement of the Dutch part of European Patent Number
1,610,766 B1. This patent, which is owned by DSP, describes and claims
amoxicillin trihydrate having a low free water content and processes for the
manufacture thereof. By its complaint, DSP seeks compensation for damages and a
permanent injunction to prevent the infringing manufacture, use, importation and
sale of CSPC's amoxicillin active pharmaceutical ingredient, and/or any drug
product that utilizes the active pharmaceutical, in the Netherlands.
"DSP has a world class intellectual property (IP) portfolio relating to our
innovative, sustainable, and environmental friendly amoxicillin
technology," said Karl Rotthier, CEO at DSP. "After having previously filed
patent litigation against Sinopharm Weiqida Pharmaceutical for patent
infringement in India and the Netherlands in January 2017, DSP will continue to
rigorously enforce its IP assets worldwide against any additional potential
infringers as it continues to invest in its innovative R&D programs directed to
enzymatic, sustainable antimicrobials and statins."
DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable
antibiotics, next-generation statins and anti-fungals. DSP develops, produces
and sells intermediates, active pharmaceutical ingredients and drug products.
Our employees worldwide work together to deliver cutting-edge generics solutions
that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices
in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a
50/50 Joint Venture of Royal DSM, a global science-based company active in
health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
Forward-looking statements
This press release may contain forward-looking statements with respect to DSM
Sinochem Pharmaceuticals' (DSP) future (financial) performance and position.
Such statements are based on current expectations, estimates and projections of
DSP and information currently available to the company. DSP cautions readers
that such statements involve certain risks and uncertainties that are difficult
to predict and therefore it should be understood that many factors can cause
actual performance and position to differ materially from these statements. DSP
has no obligation to update the statements contained in this press release,
unless required by law. The English language version of the press release is
leading.
Please visit www.dsm-sinochem.com for more information or contact
DSM Sinochem Pharmaceuticals Corporate Communications
Alice Beijersbergen, Global Director Branding & Communications
E-Mail: communications(at)dsm-sinochem.com
DSM Sinochem Pharmaceuticals
Corporate Communications
www.dsm-sinochem.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM Sinochem Pharmaceuticals via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 09.10.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 562849
Anzahl Zeichen: 4504
contact information:
Town:
Redwood City
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuan..."
steht unter der journalistisch-redaktionellen Verantwortung von
DSM Sinochem Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
